Health maintenance organization

New Research From Inovalon and Harvard Analyzes Medicare Advantage Plan Design Impact on Healthcare Utilization and Health Equity

Retrieved on: 
Monday, April 8, 2024
Harvard Medical School, HMO, Health, Preferred provider organization, Importance, Inovalon, Research, Health maintenance organization, PPO, Medicare, Medicare Advantage, FFS, Health insurance

The findings, published in the white paper " The Importance of Plan Design in Medicare Advantage ," represent the fourth installment of Inovalon’s and Harvard Medical School’s research collaboration to understand the underlying factors influencing enrollment, quality outcomes, and utilization in MA vs. FFS Medicare.

Key Points: 
  • The findings, published in the white paper " The Importance of Plan Design in Medicare Advantage ," represent the fourth installment of Inovalon’s and Harvard Medical School’s research collaboration to understand the underlying factors influencing enrollment, quality outcomes, and utilization in MA vs. FFS Medicare.
  • Previous research found that MA delivers superior quality outcomes and utilization reductions compared to FFS Medicare, even after controlling for differences in who enrolls.
  • However, until now, there was limited data on the differences within MA, and how specific MA plan designs and features impact outcomes.
  • "By understanding the populations Medicare Advantage plans attract, policymakers and health plans can come together to incentivize and deliver superior, cost-effective outcomes for every Medicare enrollee."

Infinant Health Announces Submission of Orphan Drug Designation Application

Retrieved on: 
Tuesday, April 2, 2024
ODD, Bifidobacterium longum, Health, Disease, Incidence, Partnership, Risk, Necrotizing enterocolitis, Health maintenance organization, Biomarker, Disorder, Milk, Mortality, Bacteria, Infant, Death, United, NEC, Mucus, Marketing, FDA, Food, Pharmaceutical industry

DAVIS, Calif., April 2, 2024 /PRNewswire/ -- Infinant Health, a privately-held company focused on changing the trajectory of human health, one baby at a time, announced it has filed an application with the U.S. Food and Drug Administration (FDA) to receive Orphan Drug Designation (ODD) for its drug candidate INF108 for the prevention of necrotizing enterocolitis in pre-term infants.

Key Points: 
  • DAVIS, Calif., April 2, 2024 /PRNewswire/ -- Infinant Health, a privately-held company focused on changing the trajectory of human health, one baby at a time, announced it has filed an application with the U.S. Food and Drug Administration (FDA) to receive Orphan Drug Designation (ODD) for its drug candidate INF108 for the prevention of necrotizing enterocolitis in pre-term infants.
  • The FDA grants Orphan Drug Designation status to products that treat rare diseases, providing incentives to sponsors developing drugs or biologics.
  • Orphan Drug Designation would qualify INF108 for certain benefits and incentives, including seven years of marketing exclusivity if regulatory approval is ultimately received for the designated indication, potential tax credits for certain activities, eligibility for orphan drug grants, and the waiver of certain administrative fees.
  • The receipt of Orphan Drug Designation status does not change the regulatory requirements or process for obtaining marketing approval.

Wyeth launches China's first infant formula with two types of HMOs, leading the way in HMO innovation

Retrieved on: 
Monday, March 25, 2024
Trial of the century, Urinary tract infection, Health maintenance organization, Hospital, Research, HMO, Bronchitis, Xinhua Hospital, Infant

It diminishes lower respiratory tract infections by 55%, bronchitis by 70%, and the likelihood of using antibiotics by 53%.

Key Points: 
  • It diminishes lower respiratory tract infections by 55%, bronchitis by 70%, and the likelihood of using antibiotics by 53%.
  • Meanwhile, based on this ground-breaking innovation, the domestic HMO clinical study project for Chinese infants has officially started.
  • Ms. Shiela Qiu, Regional Business Head, Wyeth Nutrition Greater China Region, stated, "We are thrilled to achieve another milestone in the Chinese infant nutrition market.
  • Wyeth Nutrition is dedicated to fostering the superior growth of the Chinese infant nutrition market, bringing together worldwide research resources and quickening local innovation, and offering Chinese newborns more complete early-life nutrition options."

Wyeth launches China's first infant formula with two types of HMOs, leading the way in HMO innovation

Retrieved on: 
Monday, March 25, 2024
HMO, Xinhua Hospital, Bronchitis, Health maintenance organization, Hospital, Research, Infant, Trial of the century, Urinary tract infection, Multimedia

This clinically proven product offers substantial advantages for the general well-being of newborns between the ages of 0 and 12 months.

Key Points: 
  • This clinically proven product offers substantial advantages for the general well-being of newborns between the ages of 0 and 12 months.
  • It diminishes lower respiratory tract infections by 55%, bronchitis by 70%, and the likelihood of using antibiotics by 53%.
  • Meanwhile, based on this ground-breaking innovation, the domestic HMO clinical study project for Chinese infants has officially started.
  • Ms. Shiela Qiu, Regional Business Head, Wyeth Nutrition Greater China Region, stated, "We are thrilled to achieve another milestone in the Chinese infant nutrition market.

Global Baby Food and Infant Formula Market Report 2024: Competition Heats Up in Baby Food Industry with Focus on Innovation

Retrieved on: 
Tuesday, March 19, 2024
Breast milk, Convenience, Food technology, Growth, Nutrient, Parent, Health maintenance organization, Research, Infant, Baby food, Safety, Supermarket, Food safety

DUBLIN, March 19, 2024 /PRNewswire/ -- The "Baby Food and Infant Formula Market Report by Type (Milk Formula, Dried Baby Food, Prepared Baby Food, Other Baby Food), Distribution Channel (Supermarkets and Hypermarkets, Pharmacies, Convenience Stores, and Others), and Region 2024-2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, March 19, 2024 /PRNewswire/ -- The "Baby Food and Infant Formula Market Report by Type (Milk Formula, Dried Baby Food, Prepared Baby Food, Other Baby Food), Distribution Channel (Supermarkets and Hypermarkets, Pharmacies, Convenience Stores, and Others), and Region 2024-2032" report has been added to ResearchAndMarkets.com's offering.
  • Parents' concerns regarding food safety and the desire for fortified nutrients essential for infant development have catalyzed the demand for premium quality baby food varieties.
  • Market observations indicate significant growth in specialized product categories, reflecting heightened consumer preferences for dietary-specific baby food solutions.
  • With continued innovation, growing health awareness, and technological advancement, the global baby food and infant formula market is set to navigate through a promising growth period, meeting the changing needs and demands of modern-day parents worldwide.

InterCure Signs Definitive Agreement to Acquire Leon Cannabis Pharmacy Chain

Retrieved on: 
Wednesday, January 31, 2024
IMCA, Cannabis, Exercise, Patient, Agreement, Transaction, Ministry, Acquisition, Health maintenance organization, Drug

(NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading medical cannabis company in Israel and outside of North America, announced today that it has entered into a share purchase agreement (the “Agreement”) with the shareholders of Leon Pharm Ltd. (the “Sellers”, and “Leon Pharm”, respectively) to purchase Leon Pharm, a leading, Israel-based pharmacy chain specializing in dispensing medical cannabis in Israel, by way of a share purchase of all of the issued and outstanding share capital of Leon Pharm (the “Transaction”).

Key Points: 
  • (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading medical cannabis company in Israel and outside of North America, announced today that it has entered into a share purchase agreement (the “Agreement”) with the shareholders of Leon Pharm Ltd. (the “Sellers”, and “Leon Pharm”, respectively) to purchase Leon Pharm, a leading, Israel-based pharmacy chain specializing in dispensing medical cannabis in Israel, by way of a share purchase of all of the issued and outstanding share capital of Leon Pharm (the “Transaction”).
  • At the closing, InterCure will cause between 1,755,000 to 1,845,000 shares of the Company to be issued to the Sellers, depending on the share price of the Company at the time of completion.
  • Established in 1988, Leon Pharm is one of the leading private pharmacy chains in Israel, specializing in the customization of pharmaceutical products and cannabis for patients along with providing a high level of professional service.
  • The CEO of InterCure, Alexander Rabinovich, stated: "The acquisition of Leon Pharm is another step towards the implementation of the new medical cannabis reform and the introduction of HMOs.

Reliq Health Technologies, Inc. Announces Expansion of Contract with Large US Health Plan, Expects to Add 50,000 New Patients to iUGO Care

Retrieved on: 
Wednesday, January 10, 2024
Chronic care management, Patient, Frankfurt Stock Exchange, Acos, TMX Group, WKN, Health care, Health, Quality of life, RHT, OTC, TSX Venture Exchange, Health maintenance organization, Mental health

The health plan operates Accountable Care Organizations (ACOs) and Health Maintenance Organizations (HMOs) in five States with over 3,000 doctors and more than 1,000,000 patients.

Key Points: 
  • The health plan operates Accountable Care Organizations (ACOs) and Health Maintenance Organizations (HMOs) in five States with over 3,000 doctors and more than 1,000,000 patients.
  • The expansion is expected to add over 50,000 new patients to Reliq’s iUGO Care platform by the end of 2025 at an average revenue of $65 per patient per month.
  • The iUGO Care Remote Patient Monitoring, Chronic Care Management and Behavioral Health Integration solutions Reliq will be providing will enable effective preventative care that allows the ACOs to achieve their cost and quality of care objectives.
  • iUGO Care allows complex patients to receive high quality care at home, improving health outcomes, enhancing quality of life for patients and families and reducing the cost of care delivery.

TytoCare and St. Luke’s Health System Forge Exclusive Health Care Partnership in Idaho

Retrieved on: 
Wednesday, November 29, 2023
Health maintenance organization, Stanford University, Entrepreneurship, Travel, Partnership, Tyto, FDA, Lung, CCO, News, Heart, AI, Patient, Human resources, Ear, Journal, ROI, Nursing

NEW YORK, Nov. 29, 2023 (GLOBE NEWSWIRE) -- TytoCare , a virtual care company enabling health plans and providers to deliver accessible, high-quality remote primary care anywhere across the country, and St. Luke’s Health System , the largest health care provider and employer in Idaho, today announced an exclusive partnership that will give its employees and members of St. Luke’s Health Plan access to care from the comfort of home.

Key Points: 
  • NEW YORK, Nov. 29, 2023 (GLOBE NEWSWIRE) -- TytoCare , a virtual care company enabling health plans and providers to deliver accessible, high-quality remote primary care anywhere across the country, and St. Luke’s Health System , the largest health care provider and employer in Idaho, today announced an exclusive partnership that will give its employees and members of St. Luke’s Health Plan access to care from the comfort of home.
  • "We are proud to work with St. Luke’s to bring virtual care to Idaho.”
    As a commitment to enhancing access to care, St. Luke’s Health Plan, a wholly-owned subsidiary of the health system founded in 2022, will offer TytoHome kits to its members beginning in 2024.
  • Luke’s Health Plan was established on the foundation of removing barriers to care and this new partnership with TytoCare is a major step forward in realizing that goal,” said Matt Wolff, President of St. Luke’s Health Plan.
  • “Our partnership with them further drives TytoCare’s mission to provide access to care from anywhere in the world.”

New Illuma Growing-up Infant Formula Now Available throughout China

Retrieved on: 
Thursday, December 21, 2023
Health maintenance organization, Infant, Research, Growth, Urinary tract infection, National Health Commission, Preschool, Food, Nutrient, HMO, Spider, Eye, Bronchitis

The industry responded favorably to the illuma HMO growing-up infant formula as soon as it was made available.

Key Points: 
  • The industry responded favorably to the illuma HMO growing-up infant formula as soon as it was made available.
  • The illuma HMO Growing-Up Infant Formula is intended as a substantially improved nutritional option for preschoolers above 3 years old.
  • With the addition of six crucial HMOs, the company's most recent infant formula product, illuma LUXA, has the highest number of HMOs of any infant formula on the market right now.
  • The introduction of the illuma HMO growing-up infant formula highlights Wyeth Nutrition's "in China, for China" commitment in addition to showcasing the company's overall strength.

New Illuma HMO Growing-up Infant Formula Now Available throughout China

Retrieved on: 
Thursday, December 21, 2023
Health maintenance organization, Urinary tract infection, Science, Infant, Life, Risk, Immune system, Health education, Multimedia, Breast milk, Human, Milk, Research, NHC, Area studies, Food, Taste, Nutrient, Health, Abdominal pain, Eye, Bifidobacterium, GMP, HMO, Pregnancy, Infection, Weather, Lactose, Respiratory system, Growth, National Health Commission, Skin, Lactation, Bronchitis, Dietary supplement

SHANGHAI, Dec. 21, 2023 /PRNewswire/ -- Wyeth Nutrition announced that its first illuma HMO growing-up infant formula added with two human milk oligosaccharides (HMOs) is now available throughout China, which makes Wyeth Nutrition the first multinational company that sells the HMO infant formula in the market just two months after two HMOs were newly authorized as food additives by China's National Health Commission (NHC). Prior to that, the company is also the first foreign company that manufactured HMO infant formula in China, just one month after NHC's approval, at the company's GMP-level factory in Suzhou. Now, Chinese consumers can order the first HMO infant formula added with two HMOs in China via various channels, including the illuma flagship store on Tmall, the Wyeth flagship store on JD.COM, and numerous offline stores across the country.

Key Points: 
  • Prior to that, the company is also the first foreign company that manufactured HMO infant formula in China, just one month after NHC's approval, at the company's GMP-level factory in Suzhou.
  • It took the lead to launch the first illuma HMO growing-up infant formula in November.
  • After the Chinese Government approved the two HMOs, Wyeth illuma reacted quickly by launching the first HMO growing-up infant formula.
  • In 2017, Wyeth Nutrition launched the first illuma HMO product in Hong Kong, to cause quite a stir for HMO formulas.